At ISPOR Europe 2025 today, MadeAi™, the GenAI-powered evidence synthesis and report generation platform for life sciences, announced the launch of new capabilities designed to streamline and accelerate global value dossier (GVD) and Joint Clinical Assessment (JCA) submissions. With these advancements, MadeAi delivers the most comprehensive, AI-native solution for evidence synthesis—streamlining literature review from protocol creation to regulatory-ready reporting while ushering a seamless transition to dossiers, JCA submissions, clinical evaluation reports (CERs), medical information requests (MIRs), quick research, and more.
“Life science teams are under pressure to deliver faster, higher-quality evidence for evolving global frameworks like the EU’s JCA,” said Gaugarin Oliver, Founder and CEO of MadeAi. “MadeAi’s latest release brings everything together—protocol design, screening, extraction, supporting foundational literature reviews, and automated dossier generation—ensuring teams move seamlessly from literature review to reporting.”
Comprehensive, End-to-End Workflow
MadeAi now provides a full continuum of support, from protocol creation to dossier submission—enabling organizations to manage every step of the evidence synthesis lifecycle within one secure, AI-native platform:
- Protocol to Reporting—unified workflow for scoping, screening, extraction, validation, and reporting.
- Life Science specific Agentic-AI Workflow—optimized collaboration between AI and human experts.
- LLM Orchestration and Quality Controls—delivering high accuracy and transparency using the best LLM for the specific task.
- Seamless GVD/JCA/CER/MIR Reporting—automated templates and structured outputs for regulatory readiness.
Best-in-Class AI Technology
Built for enterprise deployment and validated across major global pharma and med-tech clients, MadeAi offers:
- AI-native, enterprise-tested architecture that ensures compliance, scalability, and security.
- Multi-agent orchestration for adaptive, domain-specific reasoning.
- Integrated AI-aided and AI-as-Reviewer modes for faster, more rigorous screening.
- Built-in quality appraisal bias visualization for methodological rigor.
Seamless Transition from Literature Review to Reporting
With MadeAi, teams can now transition directly from literature review to submission deliverables — including GVDs, JCAs, MIR, and CERs—with GenAI-driven consistency, traceability, and accuracy.
“MadeAi empowers HEOR, Market Access, and Medical Affairs teams to reduce manual workload, shorten timelines by up to 60%, and elevate evidence quality,” added Oliver. “Our mission is simple: to help life science organizations deliver evidence that’s faster, fairer, and fully defensible.”
About MadeAi
MadeAi™ is a GenAI-powered evidence synthesis and report generation platform purpose-built for life sciences. A CapeStart affiliate, MadeAi now operates as an independent brand dedicated to accelerating systematic literature reviews, GVD and JCA submissions, and evidence generation workflows for pharmaceutical, biotech, and medical device organizations. From protocol to publication-ready deliverables, MadeAi offers both SaaS and full-service models, helping research teams achieve up to 60%-time savings and greater accuracy in their evidence programs.
Media Contacts:
Meghan Oates-Zalesky
Chief Marketing Officer for MadeAi
meghan.oates@madeai.com
617-435-2470
Mary Kae Marinac
PR Representative for MadeAi
mk@mkmarinac.com
